FDA Drug Label
GEREF (sermorelin acetate) for injection - Prescribing Information
Serono, 1997
GH SecretagoguesFDA ApprovedA
Sermorelin
GHRH 1-29
Sermorelin acetate (GHRH 1-29) is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone. FDA-approved for diagnosing and treating GH deficiency, it stimulates the pituitary gland to produce and secrete growth hormone naturally — a preferred alternative to exogenous HGH therapy for physiological GH optimization. Available by prescription through compounding pharmacies and telehealth providers.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 6
- Research grade
- A
- Experience
- 96
- Activity
- 63
Overall check-ins
Trackers & reports
Overview
About Sermorelin
Sermorelin acetate (GHRH 1-29) is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone. FDA-approved for diagnosing and treating GH deficiency, it stimulates the pituitary gland to produce and secrete growth hormone naturally — a preferred alternative to exogenous HGH therapy for physiological GH optimization. Available by prescription through compounding pharmacies and telehealth providers.
- Category
- GH Secretagogues
- Regulatory status
- FDA Approved
- Also known as
- GHRH 1-29
- Self-reports
- 36
Community
What 36 users report
36 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 90% · Mixed 10% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Sleep
145
Energy
145
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
7
Headache
7
Self-reported dose per injection
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.2 to ≥ 5 mg (open-ended top bucket)
0.2–0.4 mg
99
0.4–0.6 mg
40
1–2 mg
3
2–3 mg
2
5+ mg
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 81% said they felt similar to their last entry, 8% more positive, and 12% more negative.
Overall, repeat reporters leaned more negative than their previous entry.
Median gap between entries: 105 days · Based on 26 repeat reporters
Research
Cited research (4)
Source
PubMed
Growth hormone-releasing peptides: clinical applications
Ghigo et al., 2008
ClinicalTrials.gov
Sermorelin studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Growth hormone releasing hormone
Grossman et al., 1986
Tools
Explore more
Explore
More ways to learn about Sermorelin from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about Sermorelin?
This page summarizes 36 anonymized self-reports from PeptIQ users who track Sermorelin, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Sermorelin?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Sermorelin?
4 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Sermorelin safe to use?
This wiki does not assess safety or recommend use. Sermorelin is listed as FDA Approved. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Sermorelin?
Research, primarily in animal models, suggests Sermorelin may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Sermorelin?
Sermorelin is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Sermorelin as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Sermorelin?
The safety and effectiveness of Sermorelin have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Sermorelin?
While there are over 200 published studies on Sermorelin, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source